Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F. Lim
Observed names:
F L Lim,
F Lim,
F.L. Lim
Institutions:
Queen Mary University of London,
Barts Cancer Institute
Observed institutions:
St Bartholomew's Hospital,
Queen Mary University of London,
Princess Margaret Hospital,
Barts Cancer Institute
ORCID:
0000-0003-1360-181X
Observed ORCID:
0000-0003-1360-181X
OpenAlex ID:
A5109600965
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
2021
·
T.C. Lam
, K.C. Tsang
, et al.
·
Lung Cancer
·
72
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
2021
·
M. Johnson
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
54
PDF
FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
2021
·
J. Neal
, F. Lim
, et al.
·
Journal of Thoracic Oncology
·
8
PDF
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
2020
·
E. Felip
, F.L. Lim
, et al.
·
Annals of Oncology
·
7
LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study
2023
·
S. Peters
, B.C. Cho
, et al.
·
Immuno-Oncology Technology
·
6
PDF
380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
2020
·
T.C. Lam
, K. Tsang
, et al.
·
Annals of Oncology
·
6
1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
2023
·
F. Ghiringhelli
, E. Felip
, et al.
·
Annals of Oncology
·
5
PDF
5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
2022
·
E.B. Garon
, B.C. Cho
, et al.
·
Annals of Oncology
·
4
PDF
Liver Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Therapy
2012
·
F.L. Lim
, J. Shamash
, et al.
·
Annals of Oncology
·
2
PDF
Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study
2022
·
N Reinmuth
, M L Johnson
, et al.
·
Pneumologie
·
1
P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2019
·
F. Lim
, S. Ponce
, et al.
·
Journal of Thoracic Oncology
·
1
Durvalumab (D)+/− tremelimumab (T)+chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
2023
·
F Griesinger
, M Johnson
, et al.
·
Pneumologie
Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
2023
·
N Reinmuth
, S Peters
, et al.
·
Pneumologie
PO-1174 3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC – option during COVID-19 pandemic
2021
·
H. Wong
, F. Lim
, et al.
·
Radiotherapy and Oncology
PDF
Show more works
View as search
Works count:
14
Citation count:
166
H-index:
6
I10-index:
2
Year
Topic
Type